Publications

Project 1 Publications:

  • Chen G, Prchal JT. Polycythemia vera and its molecular basis: An update. Best Pract Res Clin Haematol. 2006;19(3):387-97.
  • Bellanne-Chantelot C, Chaumarel I, Labopin M, Bellanger F, Barbu V, De Toma C, Delhommeau F, Casadevall N, Vainchenker W, Thomas G, Najman A. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood. 2006 Jul 1;108(1):346-52.
  • Prchal, JT Does JAK2 1849G>T initiate polycythemia vera? Blood, Jul 2006; Inside Blood. 108: 8 - 9.
  • Popat U, Frost A, Liu E, Guan Y, Durette A, Vishnu R, Prchal JT. High levels of circulating CD34 cells, dacrocytes, clonal hematopoiesis, and JAK 2 mutation differentiate myelofibrosis with myeloid metaplasia from secondary myelofibrosis associated with pulmonary hypertension. Blood. 2006 107: 3486 – 3488.
  • Vahid Afshar-Kharghan and Josef Prchal. Does Janus Have Three Faces? The Hematologist, 3(6):5, 2006.
  • Prchal, JT. Erythropoietin-independent erythroid colonies: Is the molecular basis clarified? Blood, Sep 2006; Inside Blood. 108: 1431 - 1432.
  • Henshaw M, Prchal, JT.. Minireview: Uniparental Disomy in Polycythemia Vera and in Other Malignancies. The Hematologist, 4(1):5, 2007.
  • Chen GL, Liu E, Naidoo K, Popat U, Coetzer TL, Prchal JT. Idiopathic myelofibrosis without dacryocytes. Haematologica. 2006 Jun;91:ECR29
  • Xiong Z, Liu E, Yan Y, Silver RT, Yang F, Chen IH, Chen Y, Verstovsek S, Wang H, Prchal J, Yang XF. An unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions. J Immunol. 2006 Oct 1;177(7):4907-16
  • Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, Li F, Krasich R, Temm CJ, Prchal JT, Ingram DA. Re-defining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood. 2006 Oct 19
  • Nussenzveig RH, Lingam HB, Gaikwad A, Zhu Q, Jing N, Prchal JT. A novel mutation of the cytochrome-b5 reductase gene in an Indian patient: the molecular basis of type I methemoglobinemia. Haematologica. 2006 Nov;91(11):1542-5.
  • Xiong Z, Yan Y, Liu E, Silver RT, Verstovsek S, Yang F, Wang H, Prchal J, Yang X-F. Novel Tumor Antigens Elicit Anti-Tumor Humoral Immune Reactions In A Subset Of Patients With Polycythemia Vera. Clinical Immunology. 2006 Nov 16; [Epub ahead of print]
  • Nussenzveig RH, Swierczek SI, JJelinek J, Gaikwad A, Liu E, Verstovsek S, Prchal JF and Prchal JT. Polycythemia Vera is not Initiated by JAK2(V617F) Mutation. Experimental Hematology. 35: 32-38, 2007.
  • Hoffman R, Prchal JT, Samuelson S, Ciurea SO, Rondelli D. Philadelphia Chromosome-Negative Myeloproliferative Disorders: Biology and Treatment. Biol Blood Marrow Transplant. 2007 Jan;13S1:64-72.
  • Gaikwad A, Nussenzveig R, Liu E, Gottshalk S, Chang K, Prchal JT. In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2(V617F) allele. Exp Hematol. 2007 Apr;35(4):587-95.
  • Gaikwad A, Verstovsek S, Nussenzveig R, Yoon, D, Chang KT, Nussenzveig R, Cortez J, Wainchenker W, Prchal JT. Imatinib Effect on Growth and Signal Transduction in Polycythemia Vera. Exp Hematol. 2007 in press

Publications for Project 2:

  • Samuelsson J, Hasselbalch H, Bruserud O, Temerinac S, Brandberg Y, Merup M, Linder O, Bjorkholm M, Pahl HL, Birgegard G, and the Nordic study group for myeloproliferative disorders (NMPD). (2006) A Phase II Trial of Pegylated Interferon ?-2b Therapy in Polycythemia vera and Essential Thrombocythemia. Feasibility, Clinical and Biological Effects and Impact on Quality of Life.Cancer, 106: 2397-2405.
  • Samuelsson J, Mutschler M, Birgegard G, Hansen PG, Bjorkholm M, Pahl HL (2006) Limited Effects on JAK2 Mutational Status after Pegylated Interferon ?-2b Therapy in Polycythemia vera and Essential Thrombocythemia. Haematologica/The Hematology Journal, 91: 1281 - 1282.
  • Steimle C, Lehmann U, Temerinac S, Goerttler PS, Kreipe H, Meinhardt G, Heimpel H, Pahl HL (2007) Biomarker analysis in Polycythemia vera under interferon-alpha treatment: Clonality, EEC, PRV-1 and JAK2 V617F. Ann.Hematol. 86: 239 244
  • Rives S, Pahl HL, Florensa L, Bellosillo B, Neusuess A, Estella J, Debatin KM, Kohne E, Schwarz K, Cario H (2007) Molecular genetic analyses in familial and sporadic congenital primary erythrocytosis. Haematologica/The Hematology Journal, 92: 674 - 677.

Publications for Project 3:

  • The quantitative JAK2 V617F neutrophil allele burden does not correlate with thrombotic risk in essential thrombocytosis. Pemmaraju N, Moliterno AR, Williams DM, Rogers O, Spivak JL. Leukemia. 2007 May 17; [Epub ahead of print]

Project 4 Publications:

  • Zetterberg E, Vannucchi AM, Migliaccio AR, Vanchenker W, Tulliez M, Rogers R, Palmblad J. Pericyte coverage of abnormal blood vessels in myelofibrosis bone marrows. Haematologica, in press.
  • Ghinassi B, Sanchez M, Martelli F, Amabile G, Vannucchi AM, Migliaccio M, Orkin SH, Migliaccio AR, The hypomorphic Gata1low mutation alters the proliferation/ differentiation potential of the common megakaryocytic-erythroid progenitor, Blood, 2007, 109:1460-1473.
  • Guglielmelli P, Zini R, Bogani C, Salati S, Pancrazi A, Bianchi E, Mannelli F, Ferrari S, Le Bousse-Kerdiles MC, Bosi A, Barosi G, Migliaccio AR, Manfredini R, Vannucchi AM. Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms Tumor 1. Stem Cells, 2007, 25:165-173.
  • A Di Baldassarre, C Di Rico, A Di Noia, T Bonfini, A Iacone, M Marchisio, S Miscia, E Alfani, AR Migliaccio, G. Stamatoyannopoulos and G Migliaccio: Protein Kinase C (PKC)alpha is differentially activated during neonatal and adult erythropoiesis and favors expression of a reporter gene under the control of the Aγ-promoter in cellular models of hemoglobin switch. J Cell Biochem 2007, published ahead of print on Jan 9.
  • Ghinassi B, M. Verrucci, Di Noia A, Migliaccio G, Migliaccio AR. Transcriptional and prost-transcriptional growth factor control of the expression of lineage-specific transcription factors during erythroid differentiation, Exp Hematol, in press.
  • Sanchez M, Weissman IL, Pallavicini M, Valeri M, Vannucchi AM, Migliaccio G, Migliaccio AR: Differential amplification of murine bipotent megakaryocytic/erythroid “progenitor” and “precursor” cells during the recovery from acute and chronic erythroid stress. Stem Cells. 2006; 24:337-348.
  • Migliaccio, AR, Vannucchi AM, Migliaccio G., Hoffman R. Molecular advances toward the understanding of the patho-biology of idiopathic myelofibrosis. Curr Imm Rev, 2006, 2: 169-186.
  • Vannucchi AM, Villeval J-L, Wagner-Ballon O, Guglielmelli P, Migliaccio AR, Animals Models of Myelofibrosis, Source Book of Models for Biomedical Research. MP Conn, editor, The Humana Press Inc, in press
  • Migliaccio AR, Rana RA. Role of Thrombopoietin in mast cell differentiation. Ann N Y Acad Sci, 2007, in press.

Project 5 Publications:

  • Rosti V, Massa M, Vannucchi AM, Bergamaschi G, Campanelli R, Pecci A, Viarengo G, Meli V, Marchetti M, Guglielmelli P, Bruno E, Xu M, Hoffman R, Barosi G; on behalf of the Investigators of the Italian Registry of Myelofibrosis with Myeloid Metaplasia and the Myeloproliferative Disorders Research Consortium. The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. Blood Cells Mol Dis. 2007 May-Jun;38(3):280-6. Epub 2007 Mar 9 .
  • Wen-Yang Hu, Yan Zhao, Wei Zhang, Takefumi Ishii, Jun Shi, Selcuk Sozer, Edward Bruno, Valerie Lindgren, Mingjiang Xu, Ronald Hoffman. Phenotypic characterization of tumor stem cells from idiopathic myelofibrosis by IL3-Rα. Experimental Hematology, submitted.
  • Ciurea S, Merchant D, Mahmud N, Bruno E, Ishii T, Xu M, Hofman R. In vitro megakaryocytopoiesis in idiopathic myelofibrosis. Blood (in revision)
  • Shi J, Zhao Y, Ishii T, Sozer S, Bruno E, Lindgren V, Xu M, Hoffman R. Effects of chromatin modifying agents on CD34+ cells from patients with idiopathic myelofibrosis. Cancer Research (in press).
  • Hu W, Zhao Y, Ishii T, Sozer S, Shi J, Zhang W, Bruno E, Hoffman R, Xu M. Hematopoietic cell lineage distribution of MPLW515L/K mutations in patients with idiopathic myelofibrosis. Br. J. Hematol 2007 Apr 4; [Epub ahead of print].
  • Hoffman R, Prchal JT, Samuelson S, Ciurea SO, Rondelli D. Philadelphia chromosome-negative myeloproliferative disorders: biology and treatment. Biol Blood Marrow Transplant. 2007 Jan;13(1 Suppl 1):64-72.
  • Chunduri S, Dobogai LC, Peace D, Saunthararajah Y, Chen HY, Mahmud N, Quigley J, Hoffman R, Jessop E, Beri R, Rondelli D. Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 2006 Oct;38(7):477-82.
  • Ishii T, Xu M, Zhao Y, Hu W-Y, Ciurea S, Bruno E, Hofman R. Recurrence of clonal hematopoiesis after discontinuing pegylated recombinant interferon-α 2a in a patient with polycythemia vera. Leukemia. 2007 Feb;21(2):373-4.
  • Ishii T, Bruno E, Hoffman R, Xu M. Involvement of various hematopoietic cell lineages by the JAK2V617F mutation in polycythemia vera. Blood 108, 3128-3134 (2006) .
  • Hoffman R and Xu M. Is Bone Marrow Fibrosis the Real Problem? Blood 107, 3421-3422 (2006)

Other Pubblications

  • Rondelli D, Barosi G, Bacigalupo A, Prchal JT, Popat U, Alessandrino EP, Spivak JL, Smith BD, Klingemann HG, Fruchtman S, Hoffman R; Myeloproliferative Diseases-Research Consortium. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood. 2005 May 15;105(10):4115-9. Epub 2005 Jan 25. PMID: 15671439

  • Ni H, Barosi G, Rondelli D, Hoffman R. Studies of the site and distribution of CD34+ cells in idiopathic myelofibrosis.Am J Clin Pathol. 2005 Jun;123(6):833-9. PMID: 15899773

  • Xu M, Bruno E, Chao J, Ni H, Lindgren V, Nunez R, Mahmud N, Finazzi G, Fruchtman SM, Popat U, Liu E, Prchal JT, Rondelli D, Barosi G, Hoffman R. The constitutive mobilization of bone marrow-repopulating cells into the peripheral blood in idiopathic myelofibrosis. Blood. 2005 Feb 15;105(4):1699-705. Epub 2004 Oct 7. PMID: 15471948

  • Xu M, Bruno E, Chao J, Huang S, Finazzi G, Fruchtman SM, Popat U, Prchal JT, Barosi G, Hoffman R; MPD Research Consortium. Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases. Blood. 2005 Jun 1;105(11):4508-15. Epub 2005 Feb 10. PMID: 15705794

  • Massa M, Rosti V, Ramajoli I, Campanelli R, Pecci A, Viarengo G, Meli V, Marchetti M, Hoffman R, Barosi G. Circulating CD34+, CD133+, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia. J Clin Oncol. 2005 Aug 20;23(24):5688-95. PMID: 16110028 [PubMed - indexed for MEDLINE

  • Goerttler PS, März E, Johansson PL, Andreasson B, Kutti J, Moliterno AR, Marchioli R, Spivak JL, Pahl HL. Thrombotic and bleeding complicationsin four subpopulations of patients with ET defined by c-Mpl protein expression and PRV-1 mRNA levels. Haematologica 2005;90:851-3

  • Stephen Huang, Minjiang Xu, Edward Bruno, Giovanni Barosi, Josef Prchal, and Ronald Hoffman. HMGA2, a Member of the High Mobility Group Gene Family, Is Expressed at the Protein Level in Peripheral Blood CD34+ Cells of Patients with Idiopathic Myelofibrosis and Polycythemia Vera. Blood (ASH Annual Meeting Abstracts), Nov 2004; 104: 798.

  • Jaroslav F. Prchal, Guido Finazzi, Yves D. Pastore, Murali M. Chintagumpala, Josef T. Prchal McGill. Essential Thrombocythemia in Children. Blood, Nov 16, 2003, 102, (11): 3417 (Abstract).

  • Yves D. Pastore, Jerry L. Spivak, Elizabeth M. Kurczynski, Guido Finazzi, Donna DiMichele, Hulya Ozsahin, Ronald Hoffman, Heike L. Pahl, Richard T. Silver, Josef T. Prchal, Jaroslav F. Prchal. Report on 12 Children with Polycythemia Vera. Blood, Nov 16, 2003, 102 (11): 1877 (Abstract).

  • Philipp Goerttler, Edith Doerner, Peter L. Johansson, Bjoern Andreasson, Jack Kutti, Alice R. Moliterno, Roberto Marchioli, Jerry L. Spivak, Heike L. Pahl. Thrombotic Complications in Four Subpopulations of Patients with ET Defined by c-Mpl Protein Expression and PRV-1 mRNA Levels. Blood, Nov 16, 2003,102 (11): 3415

  • Yves D. Pastore, Jerry L. Spivak, Elizabeth M. Kurczynski, Guido Finazzi, Donna DiMichele, Hulya Ozsahin, Ronald Hoffman, Heike L. Pahl, Richard T. Silver, Josef T. Prchal, Jaroslav F. Prchal. Report on 12 Children with Polycythemia Vera. Blood Nov 16, 2003, 102, (11): 1877 (Abstract).

  • Damiano Rondelli, Gianni Barosi, Andrea Bacigalupo, Joseph T. Prchal, Uday Popat, Emilio P. Alessandrino, Jerry L. Spivak, Ronald Hoffman, Steven Fruchtman. Blood, Nov 16, 2003 102, (11): 695 (Abstract).

  • Philipp Goerttler, Edith Doerner, Peter L. Johansson, Bjoern Andreasson, Jack Kutti, Alice R. Moliterno, Roberto Marchioli, Jerry L. Spivak, Heike L. Pahl. [3415] Thrombotic Complications in Four Subpopulations of Patients with ET Defined by c-Mpl Protein Expression and PRV-1 mRNA Levels. Session Type: Poster Session 635-III